537.73
Medpace Holdings Inc stock is traded at $537.73, with a volume of 231.15K.
It is down -0.04% in the last 24 hours and up +17.64% over the past month.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
See More
Previous Close:
$537.92
Open:
$529.99
24h Volume:
231.15K
Relative Volume:
0.63
Market Cap:
$15.36B
Revenue:
$2.68B
Net Income/Loss:
$460.40M
P/E Ratio:
33.83
EPS:
15.8963
Net Cash Flow:
$711.00M
1W Performance:
-0.09%
1M Performance:
+17.64%
6M Performance:
-11.98%
1Y Performance:
+68.48%
Medpace Holdings Inc Stock (MEDP) Company Profile
Name
Medpace Holdings Inc
Sector
Industry
Phone
(513) 579-9911
Address
5375 MEDPACE WAY, CINCINNATI, OH
Compare MEDP vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MEDP
Medpace Holdings Inc
|
537.73 | 15.36B | 2.68B | 460.40M | 711.00M | 15.90 |
|
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
|
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-18-26 | Upgrade | TD Cowen | Sell → Hold |
| Feb-13-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-10-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Oct-02-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Sep-03-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-29-25 | Downgrade | UBS | Neutral → Sell |
| Jul-23-25 | Downgrade | TD Cowen | Hold → Sell |
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Apr-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-24-25 | Initiated | Leerink Partners | Market Perform |
| Oct-23-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-27-24 | Downgrade | UBS | Buy → Neutral |
| Sep-25-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-24 | Initiated | Truist | Hold |
| May-29-24 | Initiated | TD Cowen | Buy |
| May-28-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-24 | Initiated | Deutsche Bank | Hold |
| Feb-15-24 | Upgrade | UBS | Neutral → Buy |
| Oct-24-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-08-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-27-22 | Upgrade | UBS | Sell → Neutral |
| Sep-07-22 | Initiated | UBS | Sell |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Oct-02-20 | Upgrade | Truist | Hold → Buy |
| Jun-08-20 | Upgrade | Robert W. Baird | Underperform → Neutral |
| May-13-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Apr-30-20 | Upgrade | SunTrust | Sell → Hold |
| Apr-20-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Mar-17-20 | Downgrade | SunTrust | Hold → Sell |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Oct-31-18 | Upgrade | SunTrust | Hold → Buy |
| Sep-17-18 | Initiated | SunTrust | Hold |
| Jul-31-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-01-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-29-17 | Initiated | Raymond James | Mkt Perform |
| Jul-10-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
View All
Medpace Holdings Inc Stock (MEDP) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdi - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Medpace Backs Phase 2 Cancer Imaging Trial With [68Ga]BED003 - TipRanks
Investigation Alert: Long-Term Investors who hold shares - openPR.com
Why Medpace (MEDP) Dipped More Than Broader Market Today - Yahoo Finance
Medpace Holdings, Inc. (MEDP) Stock Analysis: Is the Current Valuation Justified Amidst Strong Revenue Growth? - DirectorsTalk Interviews
Medpace Holdings (MEDP) Rallies As A More Cautious Narrative Questions The Valuation - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation | NDAQ:MEDP | Press Release - Stockhouse
Baird downgrades Medpace stock rating to neutral, raises target to $547 By Investing.com - Investing.com Nigeria
Baird Downgrades Medpace to Neutral From Outperform, Adjusts PT to $547 From $477 - marketscreener.com
Baird downgrades Medpace stock rating to neutral, raises target to $547 - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Medpace Holdings, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMEDP - AOL.com
Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
A Look at Medpace Holdings Inc (MEDP) After 3.4% Decline -- GF V - GuruFocus
Medpace Shares Fall After Jefferies Downgrade - marketscreener.com
2026-07-07 | Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:MEDP | Press Release - Stockhouse
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026 - The Globe and Mail
Jefferies Downgrades Medpace Holdings to Hold From Buy, Adjusts Price Target to $515 From $490 - marketscreener.com
Jefferies downgrades Medpace stock rating on valuation concerns By Investing.com - Investing.com Australia
Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two… - marketscreener.com
Jefferies downgrades Medpace stock rating on valuation concerns - Investing.com
Medpace: The Recovery Narrative Looks Premature (NASDAQ:MEDP) - Seeking Alpha
Medpace Stock Outlook Turns on Backlog Quality and Cancellations - The Globe and Mail
MEDPMedpace Holdings Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, I - The National Law Review
Enterprise value to revenue forward of Medpace Holdings, Inc. – NASDAQ:MEDP - TradingView
Enterprise value to EBIT forward of Medpace Holdings, Inc. – SWB:01P - TradingView
Here's Why Medpace Holdings (NASDAQ:MEDP) Has Caught The Eye Of Investors - Moomoo
Medpace (NASDAQ: MEDP) director converts restricted stock units into common shares - Stock Titan
Medpace (MEDP) director Robert O. Kraft exercises 33 RSUs, holds 955 shares - Stock Titan
Medpace (MEDP) director converts 36 RSUs into common shares - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Connect - ACCESS Newswire
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Price to book forward of Medpace Holdings, Inc. – NASDAQ:MEDP - TradingView
Price to sales forward of Medpace Holdings, Inc. – NASDAQ:MEDP - TradingView
Medpace Holdings Inc (MEDP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to EBITDA forward of Medpace Holdings, Inc. – NASDAQ:MEDP - TradingView
Price to earnings forward of Medpace Holdings, Inc. – LSX:A2APTV - TradingView
Medpace Holdings, Inc. Actuals & Estimates (NASDAQ:MEDP) - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Medpace (MEDP) Advances While Market Declines: Some Information for Investors - Yahoo Finance
2026-06-25 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Investors to Learn More About the Investigation | NDAQ:MEDP | Press Release - Stockhouse
MEDP Forecast — Price Target — Prediction for 2027 - TradingView
Medpace Holdings Jumps as Investors Appear to Lean on Strong Fundamentals and Possible Short Covering - Moomoo
Medpace Holdings jumps as investors appear to lean on strong fundamentals and possible short covering - Quiver Quantitative
Medpace Holdings Inc Stock (MEDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):